Deltex grows production capacity:
This article was originally published in Clinica
UK haemodynamic monitoring company Deltex Medical is to raise around £1.9m ($3.8m) through the sale of over eight million new shares. The firm said it will use the proceeds to significantly expand its manufacturing capability in response to the sales growth following the start of US reimbursement coverage of its CardioQ haemodynamic monitoring system at the end of May. Deltex plans to more than double its existing production capacity, automate certain processes in the manufacture of its disposable probes, further improve the functionality of its CardioQ monitor, and continue to broaden its IP position.
You may also be interested in...
Health-system pharmacist organization assesses the evidence behind off-label use of existing drugs for COVID-19, along with top investigational prospects like Gilead’s remdesivir.
As American auto giants GM and Ford take the wheel on working with ventilator manufacturers to make the critically needed devices during the COVID-19 pandemic, two longtime quality experts explain where the device and auto companies will find common ground when it comes to quality systems.
Despite a reprieve last summer from the Trump administration’s proposed drug price rebate rule, speakers at the 25th annual Pharmacy Benefit Manager Institute kept the focus on price transparency and talked up new ways to manage drug costs for patients in need of treatment.